Publications

de Martino M, Zhuang D, Klatte T, Rieken M, Rouprêt M, Xylinas E, Clozel T, Krzywinski M, Elemento O, Shariat SF.  2014.  Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib.. Cancer Biol Ther. 15(9):1239-47.

Buqué A, Bloy N, Perez-Lanzón M, Iribarren K, Humeau J, Pol JG, Levesque S, Mondragon L, Yamazaki T, Sato A et al..  2020.  Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer.. Nat Commun. 11(1):3819.

Bhinder B, Ferguson A, Sigouros M, Uppal M, Elsaeed AG, Bareja R, Alnajar H, Eng KWha, Conteduca V, Sboner A et al..  2023.  Immunogenomic Landscape of Neuroendocrine Prostate Cancer.. Clin Cancer Res. 29(15):2933-2943.

Markowitz GJ, Havel LS, Crowley MJp, Ban Y, Lee SB, Thalappillil JS, Narula N, Bhinder B, Elemento O, Wong STc et al..  2018.  Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival.. JCI Insight. 3(13)

Elemento O, Lefranc MPaule.  2003.  IMGT/PhyloGene: an on-line tool for comparative analysis of immunoglobulin and T cell receptor genes.. Dev Comp Immunol. 27(9):763-79.

Liu H, Murphy CJ, Karreth FA, Emdal KB, White FM, Elemento O, Toker A, Wulf GM, Cantley LC.  2018.  Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer.. Cancer Discov. 8(3):354-369.

Durrans A, Gao D, Gupta R, Fischer KR, Choi H, Rayes TEl, Ryu S, Nasar A, Spinelli CF, Andrews W et al..  2015.  Identification of Reprogrammed Myeloid Cell Transcriptomes in NSCLC.. PLoS One. 10(6):e0129123.

Bovonratwet P, Kulm S, Kolin DA, Song J, Morse KW, Cunningham ME, Albert TJ, Sandhu HS, Kim HJo, Iyer S et al..  2023.  Identification of Novel Genetic Markers for the Risk of Spinal Pathologies: A Genome-Wide Association Study of 2 Biobanks.. J Bone Joint Surg Am. 105(11):830-838.

Demichelis F, Setlur SR, Banerjee S, Chakravarty D, Chen JYun Helen, Chen CX, Huang J, Beltran H, Oldridge DA, Kitabayashi N et al..  2012.  Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk.. Proc Natl Acad Sci U S A. 109(17):6686-91.

Davis M, Martini R, Newman L, Elemento O, White J, Verma A, Datta I, Adrianto I, Chen Y, Gardner K et al..  2020.  Identification of Distinct Heterogenic Subtypes and Molecular Signatures Associated with African Ancestry in Triple Negative Breast Cancer Using Quantified Genetic Ancestry Models in Admixed Race Populations.. Cancers (Basel). 12(5)

Van Emmenis L, Ku S-Y, Gayvert K, Branch JR, Brady NJ, Basu S, Russell M, Cyrta J, Vosoughi A, Sailer V et al..  2023.  The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer.. Cancer Res Commun. 3(8):1447-1459.

Musselman K, Glynn S, Mosquera JMiguel, Elemento O, Sboner A, Beltran H, Holcomb K.  2019.  Identification of a therapeutic target using molecular sequencing for treatment of recurrent uterine serous adenocarcinoma.. Gynecol Oncol Rep. 28:54-57.

Nayar U, Sadek J, Reichel J, Hernandez-Hopkins D, Akar G, Barelli PJ, Sahai MA, Zhou H, Totonchy J, Jayabalan D et al..  2017.  Identification of a nucleoside analog active against adenosine kinase-expressing plasma cell malignancies.. J Clin Invest. 127(6):2066-2080.

Campbell TL, De Silva EK, Olszewski KL, Elemento O, Llinás M.  2010.  Identification and genome-wide prediction of DNA binding specificities for the ApiAP2 family of regulators from the malaria parasite.. PLoS Pathog. 6(10):e1001165.

Hatzi K, Jiang Y, Huang C, Garrett-Bakelman F, Gearhart MD, Giannopoulou EG, Zumbo P, Kirouac K, Bhaskara S, Polo JM et al..  2013.  A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters.. Cell Rep. 4(3):578-88.

Rafii S, Kloss CC, Butler JM, Ginsberg M, Gars E, Lis R, Zhan Q, Josipovic P, Ding B-S, Xiang J et al..  2013.  Human ESC-derived hemogenic endothelial cells undergo distinct waves of endothelial to hematopoietic transition.. Blood. 121(5):770-80.

Nazha A, Elemento O, McWeeney S, Miles M, Haferlach T.  2023.  How I read an article that uses machine learning methods.. Blood Adv. 7(16):4550-4554.

Elemento O.  2024.  How Artificial Intelligence Unravels the Complex Web of Cancer Drug Response.. Cancer Res. 84(11):1745-1746.

Yaron TM, Heaton BE, Levy TM, Johnson JL, Jordan TX, Cohen BM, Kerelsky A, Lin T-Y, Liberatore KM, Bulaon DK et al..  2022.  Host protein kinases required for SARS-CoV-2 nucleocapsid phosphorylation and viral replication.. Sci Signal. 15(757):eabm0808.

Liu Y, Choi DSoon, Sheng J, Ensor JE, Liang DHwang, Rodriguez-Aguayo C, Polley A, Benz S, Elemento O, Verma A et al..  2018.  HN1L Promotes Triple-Negative Breast Cancer Stem Cells through LEPR-STAT3 Pathway.. Stem Cell Reports. 10(1):212-227.

Ranti D, Yu H, Salomé B, Bang S, Duquesne I, Wang YA, Bieber C, Strandgaard T, Merritt E, Doherty G et al..  2025.  HLA-E and NKG2A Mediate Resistance to BCG Immunotherapy in Non-Muscle-Invasive Bladder Cancer.. bioRxiv.

Wen D, Banaszynski LA, Liu Y, Geng F, Noh K-M, Xiang J, Elemento O, Rosenwaks Z, C Allis D, Rafii S.  2014.  Histone variant H3.3 is an essential maternal factor for oocyte reprogramming.. Proc Natl Acad Sci U S A. 111(20):7325-30.

Popovic R, Martinez-Garcia E, Giannopoulou EG, Zhang Q, Zhang Q, Ezponda T, Shah MY, Zheng Y, Will CM, Small EC et al..  2014.  Histone methyltransferase MMSET/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation.. PLoS Genet. 10(9):e1004566.

Ortega-Molina A, Boss IW, Canela A, Pan H, Jiang Y, Zhao C, Jiang M, Hu D, Agirre X, Niesvizky I et al..  2015.  The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development.. Nat Med. 21(10):1199-208.

Yusufova N, Kloetgen A, Teater M, Osunsade A, Camarillo JM, Chin CR, Doane AS, Venters BJ, Portillo-Ledesma S, Conway J et al..  2021.  Histone H1 loss drives lymphoma by disrupting 3D chromatin architecture.. Nature. 589(7841):299-305.